StockNews.com started coverage on shares of Surmodics (NASDAQ:SRDX – Free Report) in a research note published on Monday. The firm issued a hold rating on the stock.
Separately, Needham & Company LLC reiterated a “hold” rating on shares of Surmodics in a research note on Monday, August 5th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $50.00.
Check Out Our Latest Research Report on Surmodics
Surmodics Stock Performance
Surmodics (NASDAQ:SRDX – Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.04. Surmodics had a positive return on equity of 3.88% and a negative net margin of 1.16%. The firm had revenue of $30.34 million for the quarter, compared to analyst estimates of $30.32 million. Research analysts expect that Surmodics will post -0.47 EPS for the current year.
Institutional Trading of Surmodics
Large investors have recently bought and sold shares of the company. SG Americas Securities LLC raised its stake in shares of Surmodics by 14.7% during the 1st quarter. SG Americas Securities LLC now owns 5,138 shares of the company’s stock worth $151,000 after buying an additional 660 shares during the last quarter. Lazard Asset Management LLC increased its holdings in Surmodics by 13.4% during the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock valued at $166,000 after acquiring an additional 673 shares in the last quarter. BNP Paribas Financial Markets raised its position in Surmodics by 7.5% during the first quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company’s stock worth $202,000 after acquiring an additional 481 shares during the last quarter. Hardin Capital Partners LLC purchased a new stake in shares of Surmodics in the second quarter valued at about $206,000. Finally, Mesirow Financial Investment Management Inc. acquired a new stake in shares of Surmodics in the first quarter valued at approximately $223,000. Institutional investors and hedge funds own 96.63% of the company’s stock.
About Surmodics
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Recommended Stories
- Five stocks we like better than Surmodics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Are Penny Stocks a Good Fit for Your Portfolio?
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- What is a Death Cross in Stocks?
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.